US equities |
MU $1,088.00 ▲+4.06% NVDA $237.47 ▼-0.74% SNDK $1,692.42 ▲+1.92% SPCX $167.60 ▼-2.51% AMD $645.86 ▼-0.55% AAPL $336.67 ▲+0.91% TSLA $377.81 ▼-0.75% META $721.31 ▼-2.38%
FinancialContent

Ethos Technologies Inc. - Class A Common Stock (NQ:LIFE)

35.00 -0.05 (-0.14%)
Delayed Quote Updated: 4:00 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ethos Technologies Inc. - Class A Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Insurtech Leader Ethos Adds Industry Veteran William Wheeler to Board of Directors
Former President of Athene brings decades of insurance, retirement, and financial services leadership to support Ethos’ next stage of growth 
From Ethos Technologies Inc
Via GlobeNewswire
News headline image
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025 ↗
These 10X penny stocks have the potential to mint millionaires with enough capital but buy wisely as the risk is real. 
Via InvestorPlace
News headline image
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
Ticker symbol change to take effect on Wednesday, June 5, 2024 
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
Recap: aTyr Pharma Q4 Earnings ↗
 
Via Benzinga
News headline image
aTyr Pharma's Earnings Outlook ↗
 
Via Benzinga
News headline image
Analyst Expectations for aTyr Pharma's Future ↗
 
Via Benzinga
News headline image
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
Findings further demonstrate that NRP2 is an important new immune target in ILD and that efzofitimod modulates myeloid cells to confer anti-inflammatory benefit 
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
aTyr Pharma to Present at Upcoming Investor Conferences
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
LIFE Stock Earnings: aTyr Pharma Beats EPS, Beats Revenue for Q1 2024 ↗
LIFE stock results show that aTyr Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
aTyr Pharma to Participate in April Investor Conferences
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
3 Penny Stocks That Could Be Multibaggers in the Making: March Edition ↗
Penny stocks are incredibly risky. However, if you can handle the heat, these ideas might be worth your while. 
Via InvestorPlace
News headline image
LIFE Stock Earnings: aTyr Pharma Misses EPS for Q4 2023 ↗
LIFE stock results show that aTyr Pharma missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT 
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 14, 2024 ↗
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. 
Via Benzinga
News headline image
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
The 3 Best Penny Stocks to Buy in February 2024 ↗
With proposed FED rate cuts incoming, these are the penny stocks that are likely to see a spark into new rallies. 
Via InvestorPlace
News headline image
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
Dr. Frederick to advise Company on corporate affairs and commercial strategy for efzofitimod in interstitial lung disease (ILD). 
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
Beat of Life Entertainment's 'Diya Jalao Roshni Lao' Campaign: Lighting Up Lives and Preserving Tradition!
The "Diya Jalao Roshni Lao" campaign was initiated by the Beat of Life Entertainment company in 2022. Its aim is to draw people's attention to our culture, the hard work of potters, hope, their lives,... 
Via IssueWire
Topics Religion
News headline image
aTyr Pharma to Present at November Investor Conferences
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD
Multiple centers in the U.S. are open for enrollment 
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
$12M Bet On This Trucking Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying ↗
The Dow Jones closed higher on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks... 
Via Benzinga
News headline image
aTyr Pharma's Cash Runway Secured till 2026, Despite Lack of Material Catalysts: Oppenheimer Analyst ↗
Oppenheimer has downgraded aTyr Pharma Inc (NASDAQ: LIFE) to Perform from Outperform, citing a few material catalysts in the next few quarters. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2023 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 Next >